176 related articles for article (PubMed ID: 25543487)
21. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamagni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M;
Lancet; 2010 Dec; 376(9758):2075-85. PubMed ID: 21146205
[TBL] [Abstract][Full Text] [Related]
22. [A cohort study comparing the efficacy and safety of bortezomib plus dexamethasone versus bortezomib, epirubicin and dexamethasone in patients with multiple myeloma].
Hao QY; Chen H; Liu KY; Wen L; Huang XJ; Lu J
Zhonghua Nei Ke Za Zhi; 2016 Sep; 55(9):689-94. PubMed ID: 27586976
[TBL] [Abstract][Full Text] [Related]
23. Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure.
Pönisch W; Moll B; Bourgeois M; Andrea M; Schliwa T; Heyn S; Schmalfeld M; Edelmann T; Becker C; Hoffmann FA; Schwarzer A; Kreibich U; Egert M; Stiegler R; Krahl R; Remane Y; Bachmann A; Lindner T; Weidhase L; Petros S; Fricke S; Vucinic V; Al Ali H; Niederwieser D
J Cancer Res Clin Oncol; 2013 Nov; 139(11):1937-46. PubMed ID: 24046251
[TBL] [Abstract][Full Text] [Related]
24. [Therapeutic efficacy of bortezomib-based chemotherapy on 40 patients with multiple myeloma].
Li CM; Lu H; Wu HX; Qiu HX; Qian SX; Xu W; Li JY; Chen LJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1511-4. PubMed ID: 21176361
[TBL] [Abstract][Full Text] [Related]
25. [Bortezomib combined with other drugs for treating 60 cases of multiple myeloma].
Zhong YP; Chen SL; Li X; Hu Y; Zhang JJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):214-7. PubMed ID: 19236782
[TBL] [Abstract][Full Text] [Related]
26. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J
Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914
[TBL] [Abstract][Full Text] [Related]
27. Superior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by a free light chain- and M-protein-based model: extended follow-up of a phase II trial.
Dytfeld D; Griffith KA; Friedman J; Lebovic D; Harvey C; Kaminski MS; Jakubowiak AJ
Leuk Lymphoma; 2011 Jul; 52(7):1271-80. PubMed ID: 21699382
[TBL] [Abstract][Full Text] [Related]
28. Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma.
Ahn JS; Jung SH; Yang DH; Bae SY; Kim YK; Kim HJ; Lee JJ
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):389-94. PubMed ID: 24630919
[TBL] [Abstract][Full Text] [Related]
29. [Efficacy of bortezomib combined dexamethasone in 24 patients with multiple myeloma].
Li J; Zhao Y; Luo SK; Huang BH; Ding Y; Tong XZ; Wang HH; Zheng D; Su C; Peng AH
Ai Zheng; 2008 Apr; 27(4):429-34. PubMed ID: 18423132
[TBL] [Abstract][Full Text] [Related]
30. [Retrospective analysis of 71 cases of multiple myeloma].
Yang P; Zhang WJ; Jing HM; Ke XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1573-6. PubMed ID: 20030950
[TBL] [Abstract][Full Text] [Related]
31. Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.
Sellner L; Heiss C; Benner A; Raab MS; Hillengass J; Hose D; Lehners N; Egerer G; Ho AD; Goldschmidt H; Neben K
Cancer; 2013 Jul; 119(13):2438-46. PubMed ID: 23576287
[TBL] [Abstract][Full Text] [Related]
32. The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.
Niesvizky R; Richardson PG; Rajkumar SV; Coleman M; Rosiñol L; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau JL; Boral AL; Esseltine DL; Anderson KC; Bladé J
Br J Haematol; 2008 Oct; 143(1):46-53. PubMed ID: 18673366
[TBL] [Abstract][Full Text] [Related]
33. [Clinical feature and efficacy of patients with multiple myeloma and renal impairment treated with bortezomib based chemotherapy].
Xu Y; An G; Deng SH; Sui WW; Feng XY; Li F; Hao M; Wang YF; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):304-8. PubMed ID: 23668201
[TBL] [Abstract][Full Text] [Related]
34. Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.
Morabito F; Bringhen S; Larocca A; Wijermans P; Victoria Mateos M; Gimsing P; Mazzone C; Gottardi D; Omedè P; Zweegman S; José Lahuerta J; Zambello R; Musto P; Magarotto V; Schaafsma M; Oriol A; Juliusson G; Cerrato C; Catalano L; Gentile M; Isabel Turel A; Marina Liberati A; Cavalli M; Rossi D; Passera R; Rosso S; Beksac M; Cavo M; Waage A; San Miguel J; Boccadoro M; Sonneveld P; Palumbo A; Offidani M
Am J Hematol; 2014 Apr; 89(4):355-62. PubMed ID: 24273190
[TBL] [Abstract][Full Text] [Related]
35. Immunoglobulin D Multiple Myeloma: Disease Profile, Therapeutic Response, and Survival.
Wang GR; Sun WJ; Chen WM; Huang ZX; Zhang JJ; An N; Shen M; Li X
Acta Haematol; 2016; 136(3):140-6. PubMed ID: 27409804
[TBL] [Abstract][Full Text] [Related]
36. [Clinical significance of abnormal protein bands in multiple myeloma treated with bortezomib-based induction regimen and autologous stem cell transplantation].
Wang HH; Li J; Liu JR; Zheng D; Gu JL; Yan MS; Zou WY; Xu DR
Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):327-31. PubMed ID: 23668206
[TBL] [Abstract][Full Text] [Related]
37. Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma.
Iwama K; Chihara D; Tsuda K; Ugai T; Sugihara H; Nishida Y; Yamakura M; Takeuchi M; Matsue K
Eur J Haematol; 2013 Feb; 90(2):134-41. PubMed ID: 23210517
[TBL] [Abstract][Full Text] [Related]
38. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.
Dimopoulos M; Siegel DS; Lonial S; Qi J; Hajek R; Facon T; Rosinol L; Williams C; Blacklock H; Goldschmidt H; Hungria V; Spencer A; Palumbo A; Graef T; Eid JE; Houp J; Sun L; Vuocolo S; Anderson KC
Lancet Oncol; 2013 Oct; 14(11):1129-1140. PubMed ID: 24055414
[TBL] [Abstract][Full Text] [Related]
39. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C
Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
Morabito F; Gentile M; Ciolli S; Petrucci MT; Galimberti S; Mele G; Casulli AF; Mannina D; Piro E; Pinotti G; Palmieri S; Catalano L; Callea V; Offidani M; Musto P; Bringhen S; Baldini L; Tosi P; Di Raimondo F; Boccadoro M; Palumbo A; Cavo M
Eur J Haematol; 2010 Mar; 84(3):223-8. PubMed ID: 19930441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]